In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer.
Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale bulk sequencing data, single-cell and spatial transcriptomic data and epigenetic data.
Outside of his career at Immunitas, Tommy is a brilliant science communicator and teacher, with various educational streams, including Twitter, a blog, a GitHub repository, a YouTube channel, a newsletter, as well as authoring his own book, 'From Cell Line To Command Line'. He is passionate about teaching biologists the computational skills essential for modern science.
You will learn:
How to stay ahead of the curve: developing the data analysis and bioinformatics skills essential to modern research.
How Immunitas is developing a discovery engine to aid the fight against cancer and the computational workflows behind it.
How to transition from a biologist to a computational biologist.
About the shift from academia to industry.
About Tommy's inspiring journey.
Things mentioned:
Link to all Tommy's resources: https://tommytang.bio.link/
Shanghai Jiao Tong University
University of Florida
MOOC Platforms:
Udacity,
Coursera,
edX
Biostars
MD Anderson Cancer Center
Roel Verhaak
Cancer Genome Atlas Project
Harvard Faculty of Arts and Sciences
Shirley Liu's group at
Dana Farber
Cancer Immunological Data Commons
Mount Sinai
Stanford
Tommy's Blog: https://divingintogeneticsandgenomics.com/
Immunitas's lead candidate: CD161 / IMT-009 / KORV1
Workflow management systems:
SnakeMake,
Nextflow...
Visgene
Matthew Berstein
PD-1
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds.
Additional Materials:
Watch the recording of the live event! https://youtu.be/CYa9rDFDaaI
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
X: https://twitter.com/AntiverseHQ
